Sunepitron hydrochloride. Anxiolytic antidepressant 5-HT(1A) autoreceptor agonist α2-adrenoceptor antagonist

Drugs of the Future

Volumn 23, Issue 2, 1998, Pages 161-165

  Silvestre, J ^a   Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; AP 521; AUTORECEPTOR; BUSPIRONE; DRUG METABOLITE; FLESINOXAN; IPSAPIRONE; OSEMOZOTAN; SEROTONIN 1A AGONIST; SUNEPITRON; UNCLASSIFIED DRUG;

ANXIETY; DEPRESSION; DRUG CONJUGATION; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SYNTHESIS; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; TRANQUILIZING ACTIVITY;

EID: 0031897458     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.02.445830     Document Type: Review

References (16)

1. Bright, G.M., Desai, K.A. (Pfizer, Inc.). Bis-aza-bicyclic anxiolytic agents and antidepressants. EP 380217, JP 90233681, US 5122525, WO 9008144, WO 9008148.
2. New mechanism involved in the anxiolytic effect of flesinoxan? Prous Science Daily Essentials December 4, 1997.
3. Rollema, H., Clarke, T., Lu, Y., Schmidt, A., Sprouse, J. Comparison of the effects of CP-93,393 and buspirone on 5-HT and NE release: Microdialysis studies in the hippocampus of the freely moving rat and guinea pig. J Neurochem 1996, 66(Suppl. 2): S37.
4. 2 antagonist activities. Soc Neurosci Abst 1995, 21 (Part 3): Abst 827.5.
5. 2-adrenergic antagonist properties: In vitro studies. Soc Neurosci Abst 1995, 21(Part 3): Abst 827.4.
6. 2-adrenergic antagonist properties. J Neurochem 1996, 66(Suppl. 2): S38.
7. 2-adrenergic antagonist activities. Soc Neurosci Abst 1995, 21(Part 3): Abst 827.6.
8. Prakash, C., Soliman, V. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS. Drug Metab Dispos 1997, 25: 1288-97.
9. Prakash, C., Cui, D. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys. Identification of the novel pyrimidine ring cleaved metabolites. Drug Metab Dispos 1997, 25: 1395-406.
10. CP-93,393 development status. Pfizer, Inc. Company Communication 1997, December 2.
11. Prakash, C. Absorption and metabolism of an antianxiety drug CP-93,393 in rat: Differention of regioisomeric glucuronide conjugates by ionspray LC/MS/MS and LC/MS/MS/MS. 7th North Amer ISSX Meet (Oct 20-24, San Diego) 1996, Abst 431.
12. Lu, Y., Clarke, T., Schmidt, A.W., Sprouse, J., Rollema, H. Comparison of the effects of CP-93,393 and buspirone on NE and 5-HT release: Microdialysis studies in hippocampus of freely moving rats and guinea pig. Soc Neurosci Abst 1996, 22(Part 1): Abst 95.10.
13. Colgan, S.T., Reed, R.H., Dumont, M.L., Haggan, G.R. Assay and purity evaluation of CP-93,393-1 by reversed-phase liquid chromatography - A snapshot of current practices for LC methods development and validation. Pharm Res 1996, 13(9, Suppl.): Abst APQ-1085.
14. Weisenburger, W.P., Kozak, C.L., Medeiros, L.A., Chapman, D.S. Evaluation of a new anxiolytic antidepressant, CP-93,393: Pre-and postnatal study in rats. Teratology 1996, 53: 123.
15. Luther, E.L., Cole, M.J., Soliman, V., Baxter, J.G., Fouda, H.G. HPLC/RAM/ESI/MS/MS studies on the metabolic fate of the anxiolytic agent CP-93,393. In: Proceedings of the 44th American Society of Mass Spectrometry Conference on Mass Spectrometry and Allied Topics, Portland, 1996, 250.
16. Avery, M.J., Fouda, H.G. Quantitative determination of CP-93,393 in serum at trace levels by HPLC/MS/MS. In: Proceedings of the 44th American Society of Mass Spectrometry